Kevin B. Kim Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma? Cancer 119
Bevacizumab and other drugs targeting vascular endothelial growth factor and/or its receptor have shown encouraging clinical outcomes in early-phase studies when they are combined with cytotoxic chemotherapy drugs. The success of bevacizumab or other antiangiogenic drugs in the treatment of patients with advanced melanoma will depend on a better understanding of tumoral neovascularization and its effect on tumor stromal tissues, as well as on selecting patients with appropriate relevant biomarkers to yield improved clinical outcomes.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf